These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31683978)

  • 41. The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies.
    Behrmann L; Wellbrock J; Fiedler W
    Expert Opin Ther Targets; 2020 May; 24(5):451-462. PubMed ID: 32188313
    [No Abstract]   [Full Text] [Related]  

  • 42. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
    Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
    Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the Tumor Microenvironment of Leukemia and Lymphoma.
    Höpken UE; Rehm A
    Trends Cancer; 2019 Jun; 5(6):351-364. PubMed ID: 31208697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer.
    Chiodoni C; Sangaletti S; Colombo MP
    J Leukoc Biol; 2017 Aug; 102(2):287-292. PubMed ID: 28148719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
    Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
    PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.
    Li K; Nie H; Jin R; Wu X
    Front Immunol; 2024; 15():1397005. PubMed ID: 38779660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibodies and immunohistochemical evaluation for the diagnosis of hematological malignancies: an overview.
    O'Malley DP; Orazi A
    Methods Mol Biol; 2007; 378():91-123. PubMed ID: 18605081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In Brief: Myeloid-derived suppressor cells in cancer.
    Solito S; Pinton L; Mandruzzato S
    J Pathol; 2017 May; 242(1):7-9. PubMed ID: 28097660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force.
    Hatziioannou A; Alissafi T; Verginis P
    J Leukoc Biol; 2017 Aug; 102(2):407-421. PubMed ID: 28360184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloid regulatory cells in tumor spreading and metastasis.
    Keskinov AA; Shurin MR
    Immunobiology; 2015 Feb; 220(2):236-42. PubMed ID: 25178934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.
    Giallongo C; Parrinello NL; La Cava P; Camiolo G; Romano A; Scalia M; Stagno F; Palumbo GA; Avola R; Li Volti G; Tibullo D; Di Raimondo F
    J Cell Mol Med; 2018 Feb; 22(2):1070-1080. PubMed ID: 29218828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.
    Sun H; Li Y; Zhang ZF; Ju Y; Li L; Zhang BC; Liu B
    Int J Hematol; 2015 Nov; 102(5):579-86. PubMed ID: 26358057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Normal hematopoiesis and hematologic malignancies: role of canonical Wnt signaling pathway and stromal microenvironment.
    Seke Etet PF; Vecchio L; Bogne Kamga P; Nchiwan Nukenine E; Krampera M; Nwabo Kamdje AH
    Biochim Biophys Acta; 2013 Jan; 1835(1):1-10. PubMed ID: 22982245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
    Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of tumor-associated macrophages in hematological malignancies.
    Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
    Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.